Company intelligence / Profile preview
Oncostellae
Spainoncostellae.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oncostellae has advanced a novel GI-targeted JAK inhibitor and a non-steroidal full antagonist of the glucocorticoid receptor into clinical trials. The lead program OST‐499 is currently in a Phase I trial for colorectal cancer and other solid tumors. The company’s model focuses on developing candidates through early clinical proof-of-concept before licensing to larger pharmaceutical partners for further development and commercialization.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Oncostellae.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncostellae.